Search results
Results from the WOW.Com Content Network
Influencers such as Peter Attia, MD are currently taking the drug “off label” for its anti-aging potential. Attia said that rapamycin, “hands down [is] the most important and exciting and ...
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
[12] On March 28, 2023, Attia (with coauthor Bill Gifford) published his book Outlive: The Science & Art of Longevity . [ 13 ] According to The New York Times Magazine , the book "has been a runaway best seller since it was published this spring [of 2023]"; [ 14 ] it was No. 3 on the Amazon Charts for nonfiction as of August 24, 2023.
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa).
U.S. President-elect Donald Trump said on Tuesday he will direct his Justice Department to "vigorously pursue" the death penalty to protect Americans from "violent rapists, murderers, and monsters ...
Enjoy a month of Mediterranean diet dinner recipes featuring high-fiber whole grains, nutrient-rich veggies, lean proteins and heart-healthy fats.
Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells. Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; [4] therefore, its activity may be more attributed to its metabolite rather than the prodrug itself (despite claims to the ...
NHS England has been criticised for delays in deciding on a policy for the prescription of everolimus in the treatment of Tuberous Sclerosis. 20 doctors addressed a letter to the board in support of the charity Tuberous Sclerosis Association saying " around 32 patients with critical need, whose doctors believe everolimus treatment is their best or only option, have no hope of access to funding.